期刊文献+

先导化合物结构优化策略(四)——改善化合物的血脑屏障通透性 被引量:8

Lead compound optimization strategy(4)——improving blood-brain barrier permeability through structural modification
原文传递
导出
摘要 血脑屏障是人体的天然屏障,它在保护中枢神经系统免受外来物质干扰和伤害的同时,也阻碍了许多潜在的中枢神经系统药物进入中枢,增加了中枢神经系统药物研发的难度。本文简述了化合物透过血脑屏障研究的最新进展,从药物化学角度综述了几种通过结构优化改善化合物透过血脑屏障的方法,旨在为中枢神经系统药物的优化提供思路。常用的几种改善化合物血脑屏障通透性的策略包括:增加脂溶性、减少氢键供体、简化分子、增加刚性、降低极性表面积、剔除羧基、前药策略、修饰为主动转运体底物及规避易被P-糖蛋白识别的结构等。 Blood-brain barrier is a natural protection for human body. It protects central nervous system from the interruption and damage of xenobiotics. However, it prevents potential drugs aimed at central nervous system, thus becomes an obstruction for the development of central nervous system drugs. The recent development of blood-brain barrier permeability research and several lead optimization strategies to improve blood-brain barrier permeability are reviewed. These structure optimization methods include increasing lipophilicity, reducing hydrogen bond doners, simplifying molecule, increasing rigidity, lowering polar surface area, avoiding acid group, prodrug strategy, modifying into active transporter's substrates, as well as avoiding P-glycoorotein recognized structures.
出处 《药学学报》 CAS CSCD 北大核心 2014年第6期789-799,共11页 Acta Pharmaceutica Sinica
基金 国家杰出青年科学基金资助项目(81025017)
关键词 血脑屏障 结构优化 药物设计 中枢神经系统 blood-brain barrier structure optimization drug design central nervous system
  • 相关文献

参考文献2

二级参考文献49

  • 1Lasser KE, Allen PD, Woolhandler SJ, et al. Timing of new black box warnings and withdrawals for prescription medications[J). JAm Med Ass, 2002, 287: 2215 -2220.
  • 2Nassar AEF, Kamel AM, Clarimont C. Improving the decision?making process in structural modification of drug candidates[J]. Drug Discov Today, 2004, 9: 1055 -1064.
  • 3Fieser LF. Carcinogenic activity, structure, and chemical reactivity of polynuclear aromatic hydrocarbons[J]. Am J Cancer, 1938,34: 37-124.
  • 4Kalgutkar AS, Soglia JR. Minimizing the potential for metabolic activation in drug discovery[J]. Expert Opin Drug Metab Toxicol, 2005, I: 91-142.
  • 5Matzinger P. The danger model: a renewed sense of self[J]. Science, 2002, 296: 301-305.
  • 6Hess DA, Sisson ME, Suria H, et al. Cytotoxicity of sulfonamide reactive metabolites: apoptosis and selective toxicity of CD8(+) cells by the hydroxylamine of sulfamethoxazole[J]. FASEB J, 1999, 13: 1688-1698.
  • 7Xu J], Diaz D, O'Brien PJ. Applications of cytotoxicity assays and pre-lethal mechanistic assays for assessment of human hepatotoxicity potential[J]. Chern Bioi Interact, 2004, 150: 115-128.
  • 8Pumford NR, Haimes NC. Protein targets of xenobiotic reactive intermediates[J]. Annu Rev Pharmacol Toxicol, 1997,37: 91-117.
  • 9Yuan L, Kaplowitz N. Glutathione in liver diseases and hepatotoxicity[J]. Mol Aspects Med, 2009, 30: 29 -41.
  • 10Jollow DJ, Mitchell JR, Potter WZ, et al. Acetaminophen?induced hepatic necrosis. 2. Role of covalent binding in vivo[J]. J Pharmacol Exp Ther, 1973, 187: 195 -202.

共引文献17

同被引文献51

引证文献8

二级引证文献36

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部